Long term response on Regorafenib in non-V600E BRAF mutated colon cancer: a case report

zu Verbundenen Objekten

Standort
Deutsche Nationalbibliothek Frankfurt am Main
ISSN
1471-2407
Umfang
Online-Ressource
Sprache
Englisch
Anmerkungen
online resource.

Erschienen in
Long term response on Regorafenib in non-V600E BRAF mutated colon cancer: a case report ; volume:19 ; number:1 ; day:11 ; month:6 ; year:2019 ; pages:1-5 ; date:12.2019
BMC cancer ; 19, Heft 1 (11.6.2019), 1-5, 12.2019

Urheber
Callebout, Eduard
Ribeiro, Suzane Moura
Laurent, Stephanie
De Man, Marc
Ferdinande, Liesbeth
Claes, Kathleen B. M.
Van der Meulen, Joni
Geboes, Karen P.
Beteiligte Personen und Organisationen
SpringerLink (Online service)

DOI
10.1186/s12885-019-5763-5
URN
urn:nbn:de:101:1-2019110506022078962027
Rechteinformation
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
Letzte Aktualisierung
15.08.2025, 07:33 MESZ

Datenpartner

Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Original beim Datenpartner anzeigen

Beteiligte

  • Callebout, Eduard
  • Ribeiro, Suzane Moura
  • Laurent, Stephanie
  • De Man, Marc
  • Ferdinande, Liesbeth
  • Claes, Kathleen B. M.
  • Van der Meulen, Joni
  • Geboes, Karen P.
  • SpringerLink (Online service)

Ähnliche Objekte (12)

Differential responsiveness to BRAF inhibitors of melanoma cell lines BRAF V600E-mutated

Differential responsiveness to BRAF inhibitors of melanoma cell lines BRAF V600E-mutated

Targeted therapy with vemurafenib in BRAF(V600E)-mutated anaplastic thyroid cancer

Targeted therapy with vemurafenib in BRAF(V600E)-mutated anaplastic thyroid cancer

BRAF inhibitors in BRAF V600E-mutated ameloblastoma: systematic review of rare cases in the literature

BRAF inhibitors in BRAF V600E-mutated ameloblastoma: systematic review of rare cases in the literature

BRAF V600E -mutated serrated colorectal neoplasia drives transcriptional activation of cholesterol metabolism

BRAF V600E -mutated serrated colorectal neoplasia drives transcriptional activation of cholesterol metabolism

Dabrafenib in patients with recurrent, BRAF V600E mutated malignant glioma and leptomeningeal disease

Dabrafenib in patients with recurrent, BRAF V600E mutated malignant glioma and leptomeningeal disease

TERT expression is susceptible to BRAF and ETS-factor inhibition in BRAF V600E /TERT promoter double-mutated glioma

TERT expression is susceptible to BRAF and ETS-factor inhibition in BRAF V600E /TERT promoter double-mutated glioma

Metastatic BRAF V600E-Mutated Thyroid Carcinoma: Molecular/Genetic Profiling Brings a New Therapeutic Option

Metastatic BRAF V600E-Mutated Thyroid Carcinoma: Molecular/Genetic Profiling Brings a New Therapeutic Option

Drug-induced colitis on BRAF and MEK inhibitors for BRAF V600E-mutated non-small cell lung cancer: a case report

Drug-induced colitis on BRAF and MEK inhibitors for BRAF V600E-mutated non-small cell lung cancer: a case report

BRAF Non-V600E Mutated Metastatic Colorectal Cancer in a Young Patient: Discussion from a Case Report

BRAF Non-V600E Mutated Metastatic Colorectal Cancer in a Young Patient: Discussion from a Case Report

Encorafenib, binimetinib, and cetuximab in BRAF V600E–mutated colorectal cancer: an early post-marketing phase vigilance study

Encorafenib, binimetinib, and cetuximab in BRAF V600E–mutated colorectal cancer: an early post-marketing phase vigilance study

Validierung eines Protokolls zur manuellen, mutationsspezifischen BRAF V600E Immunhistochemie

Hochschulschrift

Validierung eines Protokolls zur manuellen, mutationsspezifischen BRAF V600E Immunhistochemie

Dabrafenib and trametinib activity in a patient with BRAF V600E mutated and microsatellite instability high (MSI-H) metastatic endometrial cancer

Dabrafenib and trametinib activity in a patient with BRAF V600E mutated and microsatellite instability high (MSI-H) metastatic endometrial cancer

Verbundene Objekte